In a recent study posted to medRxiv , researchers in Denmark examined the risk of adverse events after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron-based bivalent booster vaccination.
The Cleveland Clinic Recruits First Participant in the Multi-center U.S. Study
Oakville, Ontario (Newsfile Corp. - January 17, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol"
EQS-News: Cardiol Therapeutics Cardiol Therapeutics begins Phase II study of CardiolRx for treatment of recurrent pericarditis 16.12.2022 / 18:26 CET/CEST The issuer is solely responsible
The Cleveland Clinic and the Mayo Clinic Study Sites have been Initiated and are Eligible to Recruit ParticipantsInitiation of Additional U.S. Cardiovascular Research Centers is Planned for Q1, 2023 Oakville